Beam Therapeutics enters the second week of July with a sharp price rally colliding head-on with one of the heaviest short positions in the gene-editing space.
The stock closed at $37.92 on Tuesday, up 10.5% on the week and 29% over the past month — a meaningful move for a pre-revenue biotech that spent much of the spring trading in the low-to-mid $20s. That recovery has not persuaded short sellers to step back. Short interest remains at 28.2% of free float, an extremely high level for any stock, and has risen 5.4% over the past month even as the price has climbed. The most recent FINRA fortnightly data puts the share count at 28.3 million short, implying a days-to-cover of over 14 — an unusually long theoretical unwind for a name this size. The ORTEX short score, a composite of lending-market and positioning signals, reads 73.5 out of 100. That score has been gradually easing from a peak of 74.9 late last month, but it remains firmly elevated.
The borrow market itself, however, tells a strikingly different story. Availability is wide open — 287% of current short interest is available to lend, meaning roughly three shares are sitting ready to borrow for every one already shorted. Cost to borrow has drifted back to just 0.46%, near its lowest reading of the past 30 days and a far cry from the brief 0.85% spike seen in mid-June. The absence of any squeeze pressure in the lending pool is notable: short sellers are heavily positioned and face no meaningful mechanical friction in holding or adding to those positions. Options sentiment reinforces that directional tilt. The put/call ratio at 0.15 is well below its 20-day average of 0.18 — options flow is skewing call-heavy, which lines up with the recent price momentum but sits in contrast to the stubbornly large short book.
The Street is broadly bullish but scattered on valuation. The consensus rating is buy, with 13 buy-rated analysts. B of A Securities reiterated its Buy and $47 target as recently as July 8, while HC Wainwright held its Buy at $80. That spread — from $47 to $80 — reflects genuine uncertainty about how to price BEAM's base-editing pipeline at this stage. Bernstein carries an Outperform but cut its target modestly to $39 in May, essentially flagging the stock at current prices. The mean price target across the group is $51.36, implying roughly 35% upside from today's close — meaningful, but not decisive enough to resolve the bull-bear standoff. Bulls point to near-term catalysts across BEAM-101 (sickle cell), BEAM-302 (alpha-1 antitrypsin deficiency), and BEAM-301, while bears focus on the cash burn trajectory and the funding overhang that comes with a pre-revenue clinical-stage company running a negative EV/EBITDA of -4.7x on trailing figures.
The institutional holder base adds a layer of complexity to the short story. ARK Investment Management holds 12.1% of shares, FMR (Fidelity) 11.4%, and Farallon Capital 10.2% — three very different styles of holder sharing the cap table. FMR is notable because the insider data captures it as a 10%-plus owner that sold 284,000 shares in the June 25–26 window at prices around $35, a combined value near $10 million. CEO John Evans also sold just under 50,000 shares across June 29–30 at prices between $34.26 and $35.91, totalling roughly $1.74 million. Net insider activity over the past 90 days shows a net disposition of around $13.2 million in value. None of these are panic-sized transactions relative to the holders involved, and CEO selling into a 29% monthly rally is a common pattern at these price levels, but it does mean that both a key institutional holder and the CEO were trimming into the same week the stock was pushing higher.
The next earnings event falls on August 7. BEAM's recent record on reporting days is mixed: the June 3 print triggered a 13.4% single-day gain, while February's result dropped 10.4% on the day and continued sliding to -15% over the following week. With short interest still at 28% of float and the stock now 45% off its April lows, the setup into that August print — and any pipeline readouts between now and then — is worth watching closely.
See the live data behind this article on ORTEX.
Open BEAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
